Form 4: Armata Pharmaceuticals Director Acquires Stock Options

Todd C. Peterson, a director of Armata Pharmaceuticals, Inc., acquired stock options on February 5, 2025.

Summary

• Todd C. Peterson, a director of Armata Pharmaceuticals, Inc., filed a Form 4.
• The form reports a transaction where Peterson acquired stock options on February 5, 2025.
• The options grant the right to buy 54,343 shares of common stock at an exercise price of $2.04.
• The options vest in two tranches: 50% on February 5, 2026, and 50% on February 5, 2027, contingent upon continuous service.
• The options expire on February 5, 2035.
• Following the transaction, Peterson directly owns 54,343 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard transaction (stock option grant) that aligns a director's interests with the company's performance. There are no explicit negative indicators.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule of the options (February 5, 2026, and February 5, 2027) suggests a medium-term focus for the director's alignment with the company's performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a director's increased stake in the company through stock options, which is a common practice in the pharmaceutical industry to align management incentives with shareholder value.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options as part of their compensation packages for directors and executives.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms for incentivizing long-term performance.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, indicating that the director's interests are aligned with theirs.
• Employees may see it as a sign of confidence in the company's future.

Key Dates